Corbus Pharmaceuticals
CRBP
Market cap $108M

8.83 USD

-0.34

3.71%

At close Jun 13, 4:00 PM EDT

After hours

8.80

-0.03

0.34%

1 day

-3.71%

5 days

-4.44%

1 month

21.63%

3 months

37.54%

6 months

-41.45%

Year to date

-26.66%

1 year

-83.30%

5 years

-95.88%

10 years

-91.27%

About: Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Employees: 28

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

4% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 24

4.63% less ownership

Funds ownership: 89.92% [Q4 2024] → 85.29% (-4.63%) [Q1 2025]

13% less funds holding

Funds holding: 99 [Q4 2024] → 86 (-13) [Q1 2025]

41% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 29

56% less call options, than puts

Call options by funds: $58K | Put options by funds: $132K

57% less capital invested

Capital invested by funds: $129M [Q4 2024] → $55.4M (-$73.9M) [Q1 2025]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$40

353%

upside

Avg. target

$51

481%

upside

High target

$58

557%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

RBC Capital Brian Abrahams	557%upside $58	Outperform Maintained	7 May 2025
Oppenheimer Jeff Jones	534%upside $56	Outperform Maintained	7 May 2025
HC Wainwright & Co. Andres Maldonado	353%upside $40	Buy Maintained	7 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about CRBP published over the past 30 days

Zacks Investment Research

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

NVO, CRBP and SKYE are tapping into the booming obesity market with novel CBD-based therapies, offering alternatives amid intensifying GLP-1 competition.

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held June 3-5, 2025 in New York, NY.

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Zacks Investment Research

Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?

While CRBP's pipeline shows promise, the company's lack of marketed products remains a concern.

Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?

Zacks Investment Research

3 Unconventional Cannabis Stocks to Watch in 2025

Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.

3 Unconventional Cannabis Stocks to Watch in 2025

Zacks Investment Research

Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 764.2% in Corbus Pharmaceuticals (CRBP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 764.18% Upside in Corbus Pharmaceuticals (CRBP): Can the Stock Really Move This High?

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being conducted in the United States under an open IND.

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Zacks Investment Research

After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

Corbus Pharmaceuticals (CRBP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

After Plunging -22.69% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

Zacks Investment Research

After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

Corbus Pharmaceuticals (CRBP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging -22.9% in 4 Weeks, Here's Why the Trend Might Reverse for Corbus Pharmaceuticals (CRBP)

Zacks Investment Research

Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know

Corbus Pharmaceuticals (CRBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Corbus Pharmaceuticals (CRBP) Upgraded to Buy: Here's What You Should Know

See News Rankings

Charts implemented using Lightweight Charts™